MetaCap

Ultragenyx Pharmaceutical (RARE) vs Zenas BioPharma (ZBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zenas BioPharma (ZBIO) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, losing 33.4% versus a loss of 50.9%. Ultragenyx Pharmaceutical is the larger company by market cap ($1.68 billion vs $1.62 billion), about 1.0 times the size, while Zenas BioPharma is growing revenue faster (+100.0% vs +20.2%). Ultragenyx Pharmaceutical converts more of its revenue into profit, with a net margin of -85.4% versus -3777.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RARE-50.94%ZBIO-33.38%
+25%-21%-66%
Nov 21, 20251 yearNov 20, 2026
RARE-71.94%ZBIO+31.40%
+145%+29%-86%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RARE versus ZBIO key metrics
MetricRAREZBIO
Share price$16.48$23.85
Market cap$1.68B$1.62B
1-day change-4.30%-4.75%
YTD return-28.35%-34.32%
1-year return-50.94%-33.38%
5-year return-78.45%—
Forward P/E11.50—
EPS (TTM)$-5.17$-9.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$673.00M$10.00M
Revenue growth (YoY)+20.18%+100.00%
Net income (latest FY)$-575.00M$-377.74M
Operating margin-79.49%-3830.57%
Net margin-85.44%-3777.37%
52-week high$39.89$44.60
52-week low$12.73$13.50
Distance from 52-week high-58.69%-46.52%
Analyst consensusbuystrong_buy
Avg. price target upside+50.49%+100.75%
Average volume4.69M593.08K
Shares outstanding101.92M67.82M
Employees1,371167
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ZBIO has outperformed RARE by 17.6 percentage points over the past year.
  • Ultragenyx Pharmaceutical is more profitable, keeping -85.4 cents of every revenue dollar as net income versus -3777.4 cents for Zenas BioPharma.
  • Zenas BioPharma grew revenue faster in its latest fiscal year (+100.00% vs +20.18%).

About Ultragenyx Pharmaceutical

RARE stock →

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees

About Zenas BioPharma

ZBIO stock →

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.

Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees

RARE vs ZBIO FAQ

Which is bigger, Ultragenyx Pharmaceutical or Zenas BioPharma?

Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.68B compared with $1.62B for Zenas BioPharma (ZBIO).

Which stock has performed better over the past year, RARE or ZBIO?

ZBIO returned -33.38% over the past 12 months, compared with -50.94% for RARE (price return, excluding dividends). Past performance does not predict future results.

Are Ultragenyx Pharmaceutical and Zenas BioPharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons